ABT-494

UBS downgraded shares of AbbVie Inc (NYSE: ABBV), citing valuation and a likely delay in the U.S. biosimilar competition for Humira. Humira is AbbVie's best-selling drug approved to treat multiple indications such as rheumatoid arthritis, psoriatic arthritis and Crohn's disease, among others....